These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33754188)
1. Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia. Larsen RH; Hjalgrim LL; Degn M; Nersting J; Als-Nielsen B; Grell K; Schmiegelow K Cancer Chemother Pharmacol; 2021 Jul; 88(1):53-60. PubMed ID: 33754188 [TBL] [Abstract][Full Text] [Related]
2. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828 [TBL] [Abstract][Full Text] [Related]
3. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880 [TBL] [Abstract][Full Text] [Related]
4. Role of TPMT and ITPA variants in mercaptopurine disposition. Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Erb N; Harms DO; Janka-Schaub G Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770 [TBL] [Abstract][Full Text] [Related]
6. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957 [TBL] [Abstract][Full Text] [Related]
8. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426 [TBL] [Abstract][Full Text] [Related]
9. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia. Schmiegelow K; Bretton-Meyer U Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403 [TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469 [TBL] [Abstract][Full Text] [Related]
11. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948 [TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547 [TBL] [Abstract][Full Text] [Related]
13. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208 [TBL] [Abstract][Full Text] [Related]
14. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723 [TBL] [Abstract][Full Text] [Related]
15. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983 [TBL] [Abstract][Full Text] [Related]
16. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol. Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736 [TBL] [Abstract][Full Text] [Related]